Differential use of antivirals for treatment of patients with influenza A(H1N1)pdm09 in Germany.
Identifieur interne : 000217 ( Main/Exploration ); précédent : 000216; suivant : 000218Differential use of antivirals for treatment of patients with influenza A(H1N1)pdm09 in Germany.
Auteurs : Annicka Reuss [Allemagne] ; Manuel Dehnert ; Silke Buda ; Walter HaasSource :
- Influenza and other respiratory viruses [ 1750-2659 ] ; 2013.
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Allemagne (MeSH), Analyse de survie (MeSH), Antiviraux (usage thérapeutique), Enfant (MeSH), Enfant d'âge préscolaire (MeSH), Femelle (MeSH), Grippe humaine (anatomopathologie), Grippe humaine (complications), Grippe humaine (traitement médicamenteux), Grippe humaine (virologie), Humains (MeSH), Indice de gravité de la maladie (MeSH), Jeune adulte (MeSH), Mâle (MeSH), Nourrisson (MeSH), Nouveau-né (MeSH), Pneumopathie infectieuse (épidémiologie), Sous-type H1N1 du virus de la grippe A (isolement et purification), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Utilisation médicament (statistiques et données numériques).
- MESH :
- anatomopathologie : Grippe humaine.
- isolement et purification : Sous-type H1N1 du virus de la grippe A.
- statistiques et données numériques : Utilisation médicament.
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Antiviraux, Grippe humaine.
- virologie : Grippe humaine.
- épidémiologie : Pneumopathie infectieuse.
- Adolescent, Adulte, Adulte d'âge moyen, Allemagne, Analyse de survie, Enfant, Enfant d'âge préscolaire, Femelle, Humains, Indice de gravité de la maladie, Jeune adulte, Mâle, Nourrisson, Nouveau-né, Sujet âgé, Sujet âgé de 80 ans ou plus.
- Wicri :
- geographic : Allemagne.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Antiviral Agents (therapeutic use), Child (MeSH), Child, Preschool (MeSH), Drug Utilization (statistics & numerical data), Female (MeSH), Germany (MeSH), Humans (MeSH), Infant (MeSH), Infant, Newborn (MeSH), Influenza A Virus, H1N1 Subtype (isolation & purification), Influenza, Human (complications), Influenza, Human (drug therapy), Influenza, Human (pathology), Influenza, Human (virology), Male (MeSH), Middle Aged (MeSH), Pneumonia (epidemiology), Severity of Illness Index (MeSH), Survival Analysis (MeSH), Young Adult (MeSH).
- MESH :
- chemical , therapeutic use : Antiviral Agents.
- geographic : Germany.
- complications : Influenza, Human.
- drug therapy : Influenza, Human.
- epidemiology : Pneumonia.
- isolation & purification : Influenza A Virus, H1N1 Subtype.
- pathology : Influenza, Human.
- statistics & numerical data : Drug Utilization.
- virology : Influenza, Human.
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Severity of Illness Index, Survival Analysis, Young Adult.
Abstract
BACKGROUND
The World Health Organization recommends early antiviral treatment for patients with severe influenza illness or those at increased risk for severe illness.
OBJECTIVES
The aim of this study was to determine the proportion of cases with laboratory-confirmed A(H1N1)pdm09 infection that have been treated with antivirals in Germany during the pandemic (H1N1) 2009 and to investigate factors associated with the use of antivirals.
METHODS
We analyzed cases with laboratory-confirmed A(H1N1)pdm09 infection notified to national health authorities in Germany between week 29/2009 and week 17/2010 using multivariable logistic regression. Severity of disease was defined by pneumonia or death.
RESULTS AND CONCLUSIONS
Of 160,804 cases with laboratory-confirmed A(H1N1)pdm09 infection, 22% were treated with antivirals. Cases with severe disease were more likely to be treated with antivirals than cases without severe disease (odds ratio=1·66; 95% confidence interval: 1·46-1·89). In the group with at least one underlying medical condition, only children aged between 1 and 4 years had significant lower odds for receiving antiviral treatment compared with cases in the age group 15 to 49 years (odds ratio=0·75; 95% confidence interval: 0·6-0·94). In conclusion, the implementation of international recommendations on use of antivirals differed according to the age of patients in Germany during the pandemic (H1N1) 2009. This indicates that the potential of antivirals to prevent severe influenza might not have been fully exhausted. The reasons leading to the observed differences in patient management need to be investigated.
DOI: 10.1111/irv.12152
PubMed: 23957666
PubMed Central: PMC4634277
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Differential use of antivirals for treatment of patients with influenza A(H1N1)pdm09 in Germany.</title><author><name sortKey="Reuss, Annicka" sort="Reuss, Annicka" uniqKey="Reuss A" first="Annicka" last="Reuss">Annicka Reuss</name><affiliation wicri:level="3"><nlm:affiliation>Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Dehnert, Manuel" sort="Dehnert, Manuel" uniqKey="Dehnert M" first="Manuel" last="Dehnert">Manuel Dehnert</name></author><author><name sortKey="Buda, Silke" sort="Buda, Silke" uniqKey="Buda S" first="Silke" last="Buda">Silke Buda</name></author><author><name sortKey="Haas, Walter" sort="Haas, Walter" uniqKey="Haas W" first="Walter" last="Haas">Walter Haas</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23957666</idno><idno type="pmid">23957666</idno><idno type="doi">10.1111/irv.12152</idno><idno type="pmc">PMC4634277</idno><idno type="wicri:Area/Main/Corpus">000191</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000191</idno><idno type="wicri:Area/Main/Curation">000191</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000191</idno><idno type="wicri:Area/Main/Exploration">000191</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Differential use of antivirals for treatment of patients with influenza A(H1N1)pdm09 in Germany.</title><author><name sortKey="Reuss, Annicka" sort="Reuss, Annicka" uniqKey="Reuss A" first="Annicka" last="Reuss">Annicka Reuss</name><affiliation wicri:level="3"><nlm:affiliation>Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Dehnert, Manuel" sort="Dehnert, Manuel" uniqKey="Dehnert M" first="Manuel" last="Dehnert">Manuel Dehnert</name></author><author><name sortKey="Buda, Silke" sort="Buda, Silke" uniqKey="Buda S" first="Silke" last="Buda">Silke Buda</name></author><author><name sortKey="Haas, Walter" sort="Haas, Walter" uniqKey="Haas W" first="Walter" last="Haas">Walter Haas</name></author></analytic><series><title level="j">Influenza and other respiratory viruses</title><idno type="eISSN">1750-2659</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Antiviral Agents (therapeutic use)</term><term>Child (MeSH)</term><term>Child, Preschool (MeSH)</term><term>Drug Utilization (statistics & numerical data)</term><term>Female (MeSH)</term><term>Germany (MeSH)</term><term>Humans (MeSH)</term><term>Infant (MeSH)</term><term>Infant, Newborn (MeSH)</term><term>Influenza A Virus, H1N1 Subtype (isolation & purification)</term><term>Influenza, Human (complications)</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (pathology)</term><term>Influenza, Human (virology)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Pneumonia (epidemiology)</term><term>Severity of Illness Index (MeSH)</term><term>Survival Analysis (MeSH)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Allemagne (MeSH)</term><term>Analyse de survie (MeSH)</term><term>Antiviraux (usage thérapeutique)</term><term>Enfant (MeSH)</term><term>Enfant d'âge préscolaire (MeSH)</term><term>Femelle (MeSH)</term><term>Grippe humaine (anatomopathologie)</term><term>Grippe humaine (complications)</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (virologie)</term><term>Humains (MeSH)</term><term>Indice de gravité de la maladie (MeSH)</term><term>Jeune adulte (MeSH)</term><term>Mâle (MeSH)</term><term>Nourrisson (MeSH)</term><term>Nouveau-né (MeSH)</term><term>Pneumopathie infectieuse (épidémiologie)</term><term>Sous-type H1N1 du virus de la grippe A (isolement et purification)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Utilisation médicament (statistiques et données numériques)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Germany</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Pneumonia</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Drug Utilization</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Utilisation médicament</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Pneumopathie infectieuse</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Humans</term><term>Infant</term><term>Infant, Newborn</term><term>Male</term><term>Middle Aged</term><term>Severity of Illness Index</term><term>Survival Analysis</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Allemagne</term><term>Analyse de survie</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Humains</term><term>Indice de gravité de la maladie</term><term>Jeune adulte</term><term>Mâle</term><term>Nourrisson</term><term>Nouveau-né</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>The World Health Organization recommends early antiviral treatment for patients with severe influenza illness or those at increased risk for severe illness.</p></div><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>The aim of this study was to determine the proportion of cases with laboratory-confirmed A(H1N1)pdm09 infection that have been treated with antivirals in Germany during the pandemic (H1N1) 2009 and to investigate factors associated with the use of antivirals.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>We analyzed cases with laboratory-confirmed A(H1N1)pdm09 infection notified to national health authorities in Germany between week 29/2009 and week 17/2010 using multivariable logistic regression. Severity of disease was defined by pneumonia or death.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS AND CONCLUSIONS</b></p><p>Of 160,804 cases with laboratory-confirmed A(H1N1)pdm09 infection, 22% were treated with antivirals. Cases with severe disease were more likely to be treated with antivirals than cases without severe disease (odds ratio=1·66; 95% confidence interval: 1·46-1·89). In the group with at least one underlying medical condition, only children aged between 1 and 4 years had significant lower odds for receiving antiviral treatment compared with cases in the age group 15 to 49 years (odds ratio=0·75; 95% confidence interval: 0·6-0·94). In conclusion, the implementation of international recommendations on use of antivirals differed according to the age of patients in Germany during the pandemic (H1N1) 2009. This indicates that the potential of antivirals to prevent severe influenza might not have been fully exhausted. The reasons leading to the observed differences in patient management need to be investigated.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23957666</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1750-2659</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>6</Issue><PubDate><Year>2013</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Influenza and other respiratory viruses</Title><ISOAbbreviation>Influenza Other Respir Viruses</ISOAbbreviation></Journal><ArticleTitle>Differential use of antivirals for treatment of patients with influenza A(H1N1)pdm09 in Germany.</ArticleTitle><Pagination><MedlinePgn>1427-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/irv.12152</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The World Health Organization recommends early antiviral treatment for patients with severe influenza illness or those at increased risk for severe illness.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to determine the proportion of cases with laboratory-confirmed A(H1N1)pdm09 infection that have been treated with antivirals in Germany during the pandemic (H1N1) 2009 and to investigate factors associated with the use of antivirals.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We analyzed cases with laboratory-confirmed A(H1N1)pdm09 infection notified to national health authorities in Germany between week 29/2009 and week 17/2010 using multivariable logistic regression. Severity of disease was defined by pneumonia or death.</AbstractText><AbstractText Label="RESULTS AND CONCLUSIONS" NlmCategory="CONCLUSIONS">Of 160,804 cases with laboratory-confirmed A(H1N1)pdm09 infection, 22% were treated with antivirals. Cases with severe disease were more likely to be treated with antivirals than cases without severe disease (odds ratio=1·66; 95% confidence interval: 1·46-1·89). In the group with at least one underlying medical condition, only children aged between 1 and 4 years had significant lower odds for receiving antiviral treatment compared with cases in the age group 15 to 49 years (odds ratio=0·75; 95% confidence interval: 0·6-0·94). In conclusion, the implementation of international recommendations on use of antivirals differed according to the age of patients in Germany during the pandemic (H1N1) 2009. This indicates that the potential of antivirals to prevent severe influenza might not have been fully exhausted. The reasons leading to the observed differences in patient management need to be investigated.</AbstractText><CopyrightInformation>© 2013 John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reuss</LastName><ForeName>Annicka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dehnert</LastName><ForeName>Manuel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Buda</LastName><ForeName>Silke</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Haas</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Influenza Other Respir Viruses</MedlineTA><NlmUniqueID>101304007</NlmUniqueID><ISSNLinking>1750-2640</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004363" MajorTopicYN="N">Drug Utilization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011014" MajorTopicYN="N">Pneumonia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">A(H1N1)pdm09</Keyword><Keyword MajorTopicYN="N">H1N1 subtype</Keyword><Keyword MajorTopicYN="N">age groups</Keyword><Keyword MajorTopicYN="N">antiviral agents</Keyword><Keyword MajorTopicYN="N">influenza A virus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>07</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23957666</ArticleId><ArticleId IdType="doi">10.1111/irv.12152</ArticleId><ArticleId IdType="pmc">PMC4634277</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bull World Health Organ. 2007 Dec;85(12):923-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18278251</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2009 Dec 08;339:b5106</Citation><ArticleIdList><ArticleId IdType="pubmed">19995812</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2010 Dec 09;15(49):</Citation><ArticleIdList><ArticleId IdType="pubmed">21163179</ArticleId></ArticleIdList></Reference><Reference><Citation>Infection. 2011 Aug;39(4):341-52</Citation><ArticleIdList><ArticleId IdType="pubmed">21544585</ArticleId></ArticleIdList></Reference><Reference><Citation>Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010 Dec;53(12):1223-30</Citation><ArticleIdList><ArticleId IdType="pubmed">21161471</ArticleId></ArticleIdList></Reference><Reference><Citation>Handb Exp Pharmacol. 2012;(214):499-522</Citation><ArticleIdList><ArticleId IdType="pubmed">23027464</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2009 Oct 17;374(9698):1312-3</Citation><ArticleIdList><ArticleId IdType="pubmed">19837238</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2012 Apr 18;(4):CD002744</Citation><ArticleIdList><ArticleId IdType="pubmed">22513907</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Recomm Rep. 2011 Jan 21;60(1):1-24</Citation><ArticleIdList><ArticleId IdType="pubmed">21248682</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2011 Feb;17(2):186-92</Citation><ArticleIdList><ArticleId IdType="pubmed">21291587</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2010 May 6;362(18):1708-19</Citation><ArticleIdList><ArticleId IdType="pubmed">20445182</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2012 Nov;6(6):e143-51</Citation><ArticleIdList><ArticleId IdType="pubmed">22687171</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2011 Aug 1;53(3):277-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21677258</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2012 Aug;55(3):e18-21</Citation><ArticleIdList><ArticleId IdType="pubmed">22543024</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Infect Dis. 2010 Jun 07;10:155</Citation><ArticleIdList><ArticleId IdType="pubmed">20525408</ArticleId></ArticleIdList></Reference><Reference><Citation>Wkly Epidemiol Rec. 2011 Nov 4;86(45):497-501</Citation><ArticleIdList><ArticleId IdType="pubmed">22128380</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2012 Nov;55(9):1198-204</Citation><ArticleIdList><ArticleId IdType="pubmed">22843781</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2012 Nov;6(6):e129-33</Citation><ArticleIdList><ArticleId IdType="pubmed">22681766</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2009 Nov 4;302(17):1872-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19822627</ArticleId></ArticleIdList></Reference><Reference><Citation>Pneumologie. 2010 Mar;64(3):149-54</Citation><ArticleIdList><ArticleId IdType="pubmed">20180179</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Nov 12;361(20):1935-44</Citation><ArticleIdList><ArticleId IdType="pubmed">19815859</ArticleId></ArticleIdList></Reference><Reference><Citation>Pneumologie. 2010 Feb;64(2):124-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20143284</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2012 Apr 3;156(7):512-24</Citation><ArticleIdList><ArticleId IdType="pubmed">22371849</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Infect Dis J. 2010 Jun;29(6):495-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20035245</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2011 May;66(5):1140-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21385717</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Infect. 2013 Feb;19(2):196-203</Citation><ArticleIdList><ArticleId IdType="pubmed">22264308</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2012 Nov;18(11):1755-62</Citation><ArticleIdList><ArticleId IdType="pubmed">23092713</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country><region><li>Berlin</li></region><settlement><li>Berlin</li></settlement></list><tree><noCountry><name sortKey="Buda, Silke" sort="Buda, Silke" uniqKey="Buda S" first="Silke" last="Buda">Silke Buda</name><name sortKey="Dehnert, Manuel" sort="Dehnert, Manuel" uniqKey="Dehnert M" first="Manuel" last="Dehnert">Manuel Dehnert</name><name sortKey="Haas, Walter" sort="Haas, Walter" uniqKey="Haas W" first="Walter" last="Haas">Walter Haas</name></noCountry><country name="Allemagne"><region name="Berlin"><name sortKey="Reuss, Annicka" sort="Reuss, Annicka" uniqKey="Reuss A" first="Annicka" last="Reuss">Annicka Reuss</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeAllemagneV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000217 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000217 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeAllemagneV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23957666
|texte= Differential use of antivirals for treatment of patients with influenza A(H1N1)pdm09 in Germany.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23957666" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV4
| This area was generated with Dilib version V0.6.35. |  |